These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19739234)

  • 1. Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Cancer; 2009 Dec; 115(23):5382-93. PubMed ID: 19739234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
    Quintás-Cardama A; Cortes J
    IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homoharringtonine for the treatment of chronic myelogenous leukemia.
    Quintás-Cardama A; Cortes J
    Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
    Wang Q; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
    Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
    Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
    Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
    Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omacetaxine mepesuccinate in chronic myeloid leukemia.
    Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
    Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
    Lü S; Wang J
    J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
    Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
    Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omacetaxine mepesuccinate for the treatment of leukemia.
    Kim TD; Frick M; le Coutre P
    Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
    Li YF; Liu X; Liu DS; Din BH; Zhu JB
    Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
    [No Abstract]   [Full Text] [Related]  

  • 12. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
    Chung C
    Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
    Narayanan V; Gutman JA; Pollyea DA; Jimeno A
    Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omacetaxine as an anticancer therapeutic: what is old is new again.
    Wetzler M; Segal D
    Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors.
    Khoury HJ; Cortes J; Baccarani M; Wetzler M; Masszi T; Digumarti R; Craig A; Benichou AC; Akard L
    Leuk Lymphoma; 2015 Jan; 56(1):120-7. PubMed ID: 24650054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
    Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
    Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
    Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
    Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.
    Heiblig M; Sobh M; Nicolini FE
    Leuk Res; 2014 Oct; 38(10):1145-53. PubMed ID: 24906663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.